Free Trial
NASDAQ:IART

Integra LifeSciences Q2 2025 Earnings Report

Integra LifeSciences logo
$12.75 -0.74 (-5.49%)
Closing price 04:00 PM Eastern
Extended Trading
$13.00 +0.25 (+1.96%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Integra LifeSciences EPS Results

Actual EPS
N/A
Consensus EPS
$0.43
Beat/Miss
N/A
One Year Ago EPS
N/A

Integra LifeSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Integra LifeSciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, July 28, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Integra LifeSciences Earnings Headlines

Integra LifeSciences: Struggling, Yet Getting Cheap
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
See More Integra LifeSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Integra LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Integra LifeSciences and other key companies, straight to your email.

About Integra LifeSciences

Integra LifeSciences (NASDAQ:IART) (NASDAQ:IART) is a global medical technology company focused on regenerative technologies, neurosurgery and reconstructive surgery. Headquartered in Princeton, New Jersey, Integra develops, manufactures and markets medical devices and instruments that support critical surgical procedures across a range of clinical specialties. The company’s offerings aim to improve patient outcomes by leveraging advanced biomaterials and proprietary technologies.

Integra’s product portfolio includes dural repair solutions, soft tissue regeneration products, external cranial protection systems and instruments for minimally invasive spine and peripheral nerve surgeries. Key offerings include collagen-based matrix products for skin and wound care, synthetic dural substitutes for neuroprotective repair and specialized nerve conduits designed to facilitate peripheral nerve regeneration. Many of these products are used in hospitals, outpatient centers and reconstructive surgery clinics worldwide.

With operations spanning North America, Europe, Asia-Pacific and Latin America, Integra LifeSciences serves an extensive network of surgeons, hospitals and distribution partners. The company has grown through a combination of internal research and development initiatives and targeted acquisitions, including the addition of ACell’s regenerative tissue technologies and Codman Neurosurgery’s portfolio from Johnson & Johnson. These strategic expansions have enhanced Integra’s capabilities in biomaterials science and broadened its reach in key geographies.

Founded in 1989, Integra LifeSciences has built a reputation for innovation in surgical technologies and regenerative medicine. The company’s leadership team, led by Chief Executive Officer Peter Arduini, brings together expertise in medical device development, global commercialization and regulatory affairs. Integra continues to invest in clinical research and product development to address evolving surgical challenges and meet the needs of healthcare providers worldwide.

View Integra LifeSciences Profile

More Earnings Resources from MarketBeat